biOasis Technologies Ord Shs V.BTI.H

RE:Is Chiesi a big surprise for 2023?

[prophetoffactz]

Another factor, in Midatech's presentation Midatech's CEO stressed the importance of BTI's partnerships as part of the deal. He likely has more information about Chiesi to support the merger.

prophetoffactz wrote: Listening to the Q&A while there is no timeline the Chiesi partnership would appear to hold the most potential for a surprise in 2023. Lots of dancing around Chiesi, in a sense. Supporting this:

1) It has been 2 1/2 years since the xB3 deal was signed with Chiesi providing time for advancement to the clinic. XOMA acquired an interest.

2) BTI changed its strategic focus to Lysosomal Storage Disorders, inflammation, and neurodegeneration.

3) Hunter became BTI's lead xB3 program and this has been affirmed by Biodexa. BTI and Biodexa are willing to go head-to-head against Denali's lead Hunter program despite trailing by years. Preclinical results for xB3 Hunter are expected to be released in Q2 2023. Is there something new about this program given previous Hunter data already presented from Scarpa?

4) The deal with Oxyrane addresses Gaucher's which is the largest Lysosomal Storage Disorder. The enzyme also has application in Parkinson's.

5) Chiesi is up for potential FDA and European approval of its strategic Fabry asset in the first half of 2023. Lysosomal Storage Disorders are a strategic focus for Chiesi and with Fabry approval Chiesi controls the potential emerging standard-of-care for Fabry. Fabry is a potential multi-billion dollar asset. Being able to address the brain is a strategic must for Lysosomal Storage Disorders and the competition is on as with Denali. The brain is important for Fabry. Chiesi must move to clinic the sooner the better as a strategic imperative. With approval for Fabry xB3 becomes more strategic to Chiesi if it wishes to be a major player in the Lysosomal Storage Disorder space.

6) Saltarelli is on Chiesi's xB3 Advisory Board along with Rathjen and Mei Mei Tian. They have an inside view. Saltarelli has stayed with BTI when he has had options given his track record. BTI changed its strategic focus to Lysosomal Storage Disorders and BTI nominated Hunter as its lead xB3 asset. BTI and Biodexa are willing to go head-to-head with Denali on Hunter despite Denali's lead of years. Rathjen appears to be dancing around Chiesi in the Q&A without being able to say anything directly due to NDA.

7) With potential validation with Chiesi through to a potential IND filing in Lysosomal Storage in 2023, the increased strategic importance of Lysosomal Storage to Chiesi with Fabry approval, and Biodexa's strength through to clinical trial infrastructue a second and larger Lysosomal Storage Disorder alliance with Chiesi could be entered in 2023. Hunter and Gaucher's are significant market opportuntities with Gaucher's the largest Lysosomal Storage Disorder. Biodexa could be a development partner into the clinic. Chiesi also has a broader strategic interest in rare disease making a potential broader deal in rare disease with Chiesi possible beyond Lysosomal Storage Disorders in 2023 as Chiesi has success with the xB3 platform into the clinic.

“With this collaboration, we are taking our commitment to bringing innovative therapies to rare disease patients, including those living with LSDs, to an entirely new level,” said Giacomo Chiesi, Head of Chiesi Global Rare Diseases, a business unit of Chiesi Group. “The unique delivery method of their xB3 platform has the potential to overcome a significant challenge in the treatment of many neurological disorders, which is the ability to cross the blood brain barrier. We look forward to working closely with the Bioasis team in advancing several new LSD clinical development programs using this technology platform.” BTI News Release